Ryan Scott
Assistant Editor at OncLive
Assistant editor for @onclive. All tweets and thoughts are my own.
Articles
-
3 weeks ago |
oncnursingnews.com | Ryan Scott
Use of a 3-year structured exercise program following completed surgery with adjuvant chemotherapy yielded increased disease-free survival (DFS) and overall survival (OS) in patients with stage III or high-risk stage II colon colon cancer as well as improved patient-reported physical function and health-related fitness, per findings from the randomized phase 3 CHALLENGE trial (NCT00819208).1 These findings, which were reported ahead of the 2025 ASCO Annual Meeting, showed that when comparing...
-
3 weeks ago |
targetedonc.com | Ryan Scott
Implementing a 3-year structured exercise program following the completion of surgery and adjuvant chemotherapy led to better disease-free survival (DFS), overall survival (OS), patient-reported physical functioning, and health-related fitness among patients with stage III and high-risk stage II colorectal cancer (CRC), according to findings from the randomized phase 3 Canadian Cancer Trials Group trial, CO.21 (CHALLENGE [NCT00819208]).
-
2 months ago |
curetoday.com | Ryan Scott
The FDA has granted Rare Pediatric Disease Designation for NEO100 in the treatment of pediatric-type diffuse high-grade gliomas, a type of brain cancer.
-
Feb 15, 2025 |
oncnursingnews.com | Ryan Scott
Men with intermediate-risk prostate cancer and high prostate-specific antigen (PSA) levels before high-intensity focused ultrasound (HIFU) treatment faced a greater risk of recurrence and treatment failure, according to research presented at the 2025 ASCO Genitourinary Cancers Symposium. In this investigation of 108 men with intermediate-risk prostate cancer following HIFU, investigators found that in-field and overall recurrence on 1-year biopsy was 41% and 54%, respectively.
-
Feb 14, 2025 |
targetedonc.com | Ryan Scott
Research presented in a poster at the 2025 ASCO Genitourinary Cancers Symposium found that high prostate-specific antigen (PSA) levels before High-Intensity Focused Ultrasound (HIFU) were associated with a greater risk of overall recurrence and treatment failure in patients with intermediate-risk prostate cancer.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 62
- Tweets
- 22
- DMs Open
- No
In this episode of #OncLiveOnAir, Dr @garciamanero, of @MDAndersonNews, discusses findings from research in myelodysplastic syndromes that were presented at the 2024 EHA Congress. #MedEd #Hematology https://t.co/XYXKhrDdCr https://t.co/o1iqAvGnSo
Hear updates from the experts themselves on #OncLiveOnAir. This week, tune in to hear from Dr @DrRaviSalgia, of @cityofhope, as he shares how he chooses b/w tepotinib & capmatinib in pts w/ stage IV NSCLC harboring MET exon 14 skipping mutations. #lcsm https://t.co/pEXFbofrlN https://t.co/jtsBl9ngYh
❗ ICYMI: NXP800 was granted orphan drug designation by the @US_FDA for the treatment of ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers.💡 Read more from @OncLive here: https://t.co/7VFKAa08bp
